Home > Formulary : Paediatric > Paediatric Chapters > 6. Endocrine system >
BNSSG Paediatric Joint Formulary
6.2 Corticosteroid responsive conditions
Last edited: 31-01-2024
6.2 Corticosteroid responsive conditions
First line drugs |
Second line drugs |
Specialist drugs |
Secondary care drugs |
-
See 'Neonatal and Paediatric Pharmacists Group Position statement 2021-22 on Use of Steroid Medication Warning Cards for Children and Young People' here
-
The 'Paediatric Steroid Treatment Card for Adrenal Insufficiency' is available to download from the British Society for Paediatric Endocrinology and Diabetes (BSPED) here
Betamethasone (parenteral) (TLS Amber Specialist Recommended)
Methylprednisolone (parenteral) (TLS Amber Specialist Recommended)
Prednisolone (oral) (TLS Green)
Dexamethasone (oral & parenteral) (TLS Green)
Hydrocortisone (parenteral) (TLS Amber Specialist Recommended)
6.2.1 Steroid Replacement Therapy
Fludrocortisone - mineralocorticoid (oral) (TLS Amber Specialist Recommended)
Hydrocortisone - glucocorticoid (oral) (TLS Amber Specialist Recommended)
Hydrocortisone (Alkindi®) (TLS Amber Specialist Recommended)
- To be initiated for adrenal insufficiency in children from birth to <6 years old in whom oral feeding is established and require less than 5mg dose.
Hydrocortisone (Efmody®) (TLS Amber Specialist Recommended)
- For congenital adrenal hyperplasia in adolescents aged 12 years and over who are not adequately controlled or have experienced androgen excess with immediate release hydrocortisone. Long-term use of Efmody® permitted only if long-term benefit on hormone profile has been demonstrated.
6.2.2 Steroid Responsive Therapy
Hydrocortisone sodium phosphate (parenteral) (TLS Green)
- BCH for emergency use when unwell
- BCH guidance for sickness if taking regular steroids
Hydrocortisone sodium succinate (Solucortef®) (parenteral) (TLS Green)
6.2.3 Cushing's syndrome and disease
Specific indication:
Metyrapone (TLS Red)
- Management of Cushing's syndrome